| Literature DB >> 29130934 |
Alexia T Kedves1, Scott Gleim1, Xiaoyou Liang1, Dennis M Bonal2, Frederic Sigoillot1, Fred Harbinski1, Sneha Sanghavi3, Christina Benander1, Elizabeth George1, Prafulla C Gokhale2, Quang-De Nguyen2, Paul T Kirschmeier2, Robert J Distel2, Jeremy Jenkins1, Michael S Goldberg2, William C Forrester1.
Abstract
Transcriptional repression of ubiquitin B (UBB) is a cancer-subtype-specific alteration that occurs in a substantial population of patients with cancers of the female reproductive tract. UBB is 1 of 2 genes encoding for ubiquitin as a polyprotein consisting of multiple copies of ubiquitin monomers. Silencing of UBB reduces cellular UBB levels and results in an exquisite dependence on ubiquitin C (UBC), the second polyubiquitin gene. UBB is repressed in approximately 30% of high-grade serous ovarian cancer (HGSOC) patients and is a recurrent lesion in uterine carcinosarcoma and endometrial carcinoma. We identified ovarian tumor cell lines that retain UBB in a repressed state, used these cell lines to establish orthotopic ovarian tumors, and found that inducible expression of a UBC-targeting shRNA led to tumor regression, and substantial long-term survival benefit. Thus, we describe a recurrent cancer-specific lesion at the level of ubiquitin production. Moreover, these observations reveal the prognostic value of UBB repression and establish UBC as a promising therapeutic target for ovarian cancer patients with recurrent UBB silencing.Entities:
Keywords: Genetics; Oncology; Ubiquitin-proteosome system
Mesh:
Substances:
Year: 2017 PMID: 29130934 PMCID: PMC5707153 DOI: 10.1172/JCI92914
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808